Indogulf Cropsciences IPO analysis

Indogulf Cropsciences IPO (initial public offering) will open for subscription on June 26, 2025 and close on June 30, 2025. Below is a breakdown of the agrochemical manufacturer’s strengths, weaknesses and growth prospects to help investors make an informed decision.

Indogulf Cropscience IPO in a nutshell

• Quality: During FY22-24, the company reported an average return on equity (ROE) and return on capital employed (ROCE) of 13 per cent each.
• Growth: Between FY22 and FY24, its revenue and net profit grew around 6.5 and 3.5 per cent per annum, respectively.
• Valuation: At the upper price band of Rs 111, the stock is expected to be valued at a P/E and P/B ratio of around 20.3 and 1.6 times, respectively. In comparison, its peers are trading at a median P/E of 29.7 times and an average P/B of nearly 2.2 times.
• Overview: Indogulf Cropsciences, a crop protection chemical maker, is expected to benefit from India’s growing demand for pesticides and the China-plus-one sourcing shift. However, its heavy reliance on imported actives, intense industry competition and monsoon-linked demand are key risks for the company.

About Indogulf Cropsciences

Indogulf Cropsciences is a Delhi-based agro-inputs manufacturer with a fully integrated presence across crop protection, plant nutrients, and biologicals. It operates four manufacturing units across Haryana and Jammu & Kashmir.

In FY24, crop protection products accounted for 91.6 per cent of revenue, followed by biologicals at 5 per cent and nutrients at 3.4 per cent. B2C customers accounted for 51.6 per cent of its revenue, followed by B2B at 35.2 per cent. Exports made up 13.2 per cent of sales.

Strengths of Indogulf Cropsciences

• Strong distribution network: The company has more than 6,900 domestic distributors that cater to farmers in 22 states and three Union Territories. Complementing its local footprint, the company exports finished formulations to over 34 countries. As of April 30, 2025, it had secured about 150 product registrations across 17 foreign markets.

Weaknesses of Indogulf Cropscience

• Long working capital cycle: Since pesticide demand surges after good rains and slumps when monsoon is patchy, the company’s inventories and collections are highly erratic. Its net working capital cycle was 200 days long in FY24. The sector’s seasonality and the company’s long cash cycle forces it to lean heavily on short-term credit.

Risk report

Company and business

• Will the company be able to scale up its business?

Yes. The Indian pesticide market is projected to grow 8.8 per cent annually through 2029, with domestic production capacity expected to rise 4 to 6  per cent per annum, led by export tailwinds and China plus one strategy. This provides ample opportunity for the company to scale up its business. 

• Does the company have recognisable brands with client stickiness?

No. While Indogulf does sell under recognised labels, pesticides are commoditised in nature, with many other players operating in the market. 

• Does the company have a credible moat?

No. Indogulf mainly markets off-patent formulations in a sector crowded with many organised players. 

Financials

• Was the company's operating cash flow positive during the last three years?

No. The company's operating cash flow has been negative from FY22 to FY23.

• Is the company free from reliance on huge working capital for day-to-day affairs?

No. Indogulf recorded a working capital cycle of around 200 days in FY24. With no history of consistent cash flows and heavy reliance on short-term debt, the business is working capital heavy.

• Can the company run its business without relying on external funding in the next three years?

No. Nearly 41 per cent of the IPO proceeds will be used to meet working capital needs. With volatile cash flows and the capital-heavy nature of the business, the company would have to rely on external funding for its operations.

Assessing an IPO requires a careful evaluation of a company's strengths, weaknesses, and growth potential, just like we've outlined for Indogulf Cropsciences. But wealth creation can only be achieved through a well-researched, balanced stock portfolio.

Our Value Research Stock Advisor can help with that. What do you get? Meticulously researched stock recommendations and ready-to-invest portfolios, updated every month.  Subscribe to Value Research Stock Advisor today and take charge of your financial future.

Disclaimer: This story is not a stock recommendation. Investors should do their due diligence before investing.

Also read: HDB Financial Services IPO analysis